

Hindawi Publishing Corporation  
The Scientific World Journal  
Volume 2013, Article ID 748979, 8 pages  
<http://dx.doi.org/10.1155/2013/748979>



## Research Article

# NCK2 Is Significantly Associated with Opiates Addiction in African-Origin Men

Zhifa Liu,<sup>1</sup> Xiaobo Guo,<sup>1,2</sup> Yuan Jiang,<sup>3</sup> and Heping Zhang<sup>1</sup>

<sup>1</sup> Department of Biostatistics, Yale University School of Public Health, New Haven, CT 06520, USA

<sup>2</sup> Department of Statistical Science, School of Mathematics and Computational Science, Sun Yat-sen University, Guangzhou 510275, China

<sup>3</sup> Department of Statistics, Oregon State University, Corvallis, OR 97331, USA

Correspondence should be addressed to Heping Zhang; [heping.zhang@yale.edu](mailto:heping.zhang@yale.edu)

Received 31 December 2012; Accepted 18 January 2013

Academic Editors: J. Ma and B. Shen

Copyright © 2013 Zhifa Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Substance dependence is a complex environmental and genetic disorder with significant social and medical concerns. Understanding the etiology of substance dependence is imperative to the development of effective treatment and prevention strategies. To this end, substantial effort has been made to identify genes underlying substance dependence, and in recent years, genome-wide association studies (GWASs) have led to discoveries of numerous genetic variants for complex diseases including substance dependence. Most of the GWAS discoveries were only based on single nucleotide polymorphisms (SNPs) and a single dichotomized outcome. By employing both SNP- and gene-based methods of analysis, we identified a strong (odds ratio = 13.87) and significant ( $P$  value =  $1.33E-11$ ) association of an SNP in the *NCK2* gene on chromosome 2 with opiates addiction in African-origin men. Codependence analysis also identified a genome-wide significant association between *NCK2* and comorbidity of substance dependence ( $P$  value =  $3.65E-08$ ) in African-origin men. Furthermore, we observed that the association between the *NCK2* gene ( $P$  value =  $3.12E-10$ ) and opiates addiction reached the gene-based genome-wide significant level. In summary, our findings provided the first evidence for the involvement of *NCK2* in the susceptibility to opiates addiction and further revealed the racial and gender specificities of its impact.

## 1. Introduction

Substance dependence is believed to result from a combination of genetic and environmental factors. Since substance dependence is a chronic brain disease, with high relapse rates, it causes serious social, economic, and medical consequences [1–3]. The World Health Organization (WHO) and the United Nations Office on Drugs and Crime (UNODC) reported that opiates dependence is associated with a high risk of HIV infection when opiates are injected using contaminated injection equipment [4]. Paulozzi et al. in 2006 reported that the number of deaths which involved prescription opioid analgesics increased from 2,900 in 1999 to at least 7,500 in 2004, an increase of 160% in just 5 years [5]. All available evidence indicated that the increasing numbers of deaths are significantly correlated to the increasing use of prescription drugs, especially opioid painkillers, among

people during the working years of life. While exposure to drugs is the prerequisite for addiction, the most important question is as follows: who will be addicted after the exposure? Genes are believed to be a major factor, although it is most likely that there are multiple genes as well as gene-environment interactions. For this reason, understanding the genetic mechanisms behind vulnerability to drug addiction is critical to improve the quality of overall health and life.

Linkage and genome-wide association studies (GWASs) have implicated many regions and genes for dependence on alcohol, tobacco, and opiates. *GABRA2*, *CHRM2*, *ADH4*, *PKNOX2*, *GABRG3*, *TAS2R16*, *SNCA*, *OPRK1*, and *PDYN* have all been associated with alcohol dependence with various degrees of replication [6–21]. Associations of other candidate alcohol dependence genes, such as *KIAA0040*, *ALDH1A1*, and *MANBA* [18, 20, 22–25], remain to be confirmed. Several groups reported *CHRNA5*, *CHRNA3*,

CHRNA4, and CSMD1 to be associated with nicotine dependence [26–34]. Meanwhile, recent studies also reported that a group of genes, such as OPRM1 [35–37], OPRD1, OPRK1 [21, 38, 39], HTR1B [40], SLC6A4 [41], GABRG2 [42], and BDNF [43], to be associated or in linkage with opiates addiction.

Complex diseases may involve heterogeneous genetic effects in different ethnic and gender groups [7, 44–47]. Luo et al. [44] reported that African-origin smokers become dependent at a lower threshold (number of cigarettes per day) than European-origin smokers. Hartel et al. [46] found that men are more vulnerable to addiction when compared to women. In addition, Chen et al. [7] revealed that *PKNOX2* is associated with drug addiction in European-origin women. These examples underscore the necessity to consider demographic or even other covariates in genetic association studies.

Many of the reported genetic variants have been identified through single SNP association tests. Despite many of the successes, a single SNP tends to have a small effect, and the single SNP-based association tests require a very stringent significance level, which is likely a key factor to the so-called “missing heritability” problem [48, 49]. To overcome some of these limitations, gene-based analysis [50–52] has emerged to jointly analyze the SNPs within genes. Gene-based methods are less affected by the heterogeneity of a single locus; hence the results may be more robust across populations [53], which increases the likelihood of replication. Hence, we performed both single SNP-based and gene-based association analyses for the data from the Study of Addiction: Genetics and Environment (SAGE) [6] which includes well-characterized phenotypic data on substance dependence including addiction to nicotine, alcohol, marijuana, cocaine, opiates, and other drugs. In our analysis, we find a genome-wide significant association of *NCK2* gene on chromosome 2 with opiates dependence in African-origin men at both the SNP and gene levels. *NCK2* is a member of NCK family of adaptor proteins, which is associated with tyrosine-phosphorylated growth factor receptors of their cellular substrates [54]. However, to the best of our knowledge, *NCK2* has not been reported to be associated with any drug addiction outcomes in humans.

## 2. Materials and Methods

Phenotypes for multisubstance dependency and genome-wide SNP data from SAGE [6] were downloaded from dbGaP (<http://www.ncbi.nlm.nih.gov/gap>). SAGE is a large case-control association study which investigates the genetic variants for drug addiction. The samples were collected from three large-scale genome-wide association studies: Collaborative Study on the Genetic of Alcoholism (COGA), the Family Study of Cocaine Dependence (FSCD), and the Collaborative Genetic Study of Nicotine Dependence (COGEN) [16, 44, 55, 56]. The original data set contains 4,121 subjects with six categories of substance dependence data: addiction to alcohol, cocaine, marijuana, nicotine, opiates, and other drugs. Lifetime dependence on these six substances is diagnosed by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The genotyping was

TABLE 1: Descriptive statistics of the key variables in the SAGE dataset stratified by sex and race.

	Black men	White men	Black women	White women	Overall
<i>n</i>	535	1131	568	1393	3627
Age (SD) yr.	40.9 (8.2)	38.7 (10.3)	39.7 (6.7)	38.2 (9.1)	39 (9.1)
Alcohol (%)	62.1	62.3	39.4	31.1	46.7
Cocaine (%)	46.4	27.3	36.3	12.5	25.8
Marijuana (%)	25.4	25.2	13.7	8.7	17.1
Nicotine (%)	47.5	46.7	47.7	41.1	44.8
Opiates (%)	8.2	9.9	6.2	4.8	7.1
Other drugs (%)	11.4	18	6.5	9.4	11.9
No drug (%)	27.1	31	38.9	50.1	39

performed by the illumina Human 1M platform. In this study, we followed a quality control/quality assurance process similar to previous analyses [7, 57]. Individuals with call rates <90% and SNPs with minor allele frequency MAF <1% were excluded from the analysis. The *P* value for the Hardy-Weinberg equilibrium was set up by >0.0001. These steps reduced the level of noise in genotypes and increased the efficiency of analysis. There are 60 duplicate genotype samples and 9 individuals with ethnic backgrounds other than African origin or European origin. All of those individuals were removed from the subject list. Finally, there were a total of 3,627 unrelated samples with 859,185 autosomal SNPs for our final analysis. To alleviate the confounding by population substructure, we stratified the sample by race and sex. Finally, there are four sub-samples: 1,393 European-origin women, 1,131 European-origin men, 568 African-origin women and 535 African-origin men. The distribution of subjects diagnosed with lifetime dependence on substances in each of the six categories: nicotine, alcohol, marijuana, cocaine, opiates, or other drugs are presented in Table 1.

## 3. Methods

Figure 1 displays the flow chart of our analytic strategy, and the details of the association analysis methods are described later.

**3.1. Statistical Analysis for Single Trait.** The SNP-based association is performed by the standard allelic test and logistic regression to obtain the *P* values for individual SNPs, and PLINK software (version 1.07) was used for analysis [58]. Meanwhile, a list of SNP pairs in linkage disequilibrium (LD) ( $r^2 > 0.2$ ) is calculated for the gene-based association test.

For the gene-based analysis, we used the open-source tool: Knowledge-Based Mining System for Genome-Wide Genetic Studies (KGG, version 2.0)—based on the SNP association test results and LD files produced by PLINK. The procedure was performed as the following. We first calculate the effective number  $m_e$  of independent *P* value among *m* SNPs within a gene. Then, we sort the SNPs and calculate the effective number  $m_{e(j)}$  of independent *P*-values among the




FIGURE 1: The pipeline of the association analysis.

top  $j$  significant SNPs. Finally, the modified Simes test [51] was employed to obtain a gene-based  $P$  value as follows,

$$P_G = \text{Min} \left( \frac{m_e P_{(j)}}{m_{e(j)}} \right), \quad (1)$$

where  $P_{(j)}$  is the  $j$ th most significant among the  $m$  SNPs within a gene. We refer the interested readers to [51] for details.

In the gene-based method, SNPs within 20 kilo bases (kb) 5' upstream and 10 kilo bases (kb) 3' downstream of a gene's coding regions [59] were assigned to the gene. In addition, we included other SNPs if they are in strong LD ( $r^2 > 0.9$ ) with the initially mapped SNPs within the gene [60].

Since there are about 20,000 protein coding genes in human genome, we used  $0.05/20,000 = 2.5 \times 10^{-6}$  as the genome-wide significance threshold for the gene-based association test. In contrast, we used  $5.0 \times 10^{-8}$  as the genome-wide significance threshold for the SNP-based association test [61].

**3.2. Codependence Association Analysis.** Although logistic regression is commonly used to study a binary outcome, it is not suitable to evaluate comorbidity involving multiple outcomes. We use a nonparametric association test based on Kendall's tau [62] to study the comorbidity. The Kendall's tau-based association test proceeds as follows.

Suppose that we observe a  $p$ -dimensional vector of traits  $Y_i = (Y_i^{(1)}, \dots, Y_i^{(p)})^T$ , genotype  $G_i$ , and a  $q$ -dimensional vector of covariates  $Z_i = (Z_i^{(1)}, \dots, Z_i^{(q)})^T$  for the  $i$ th subject in a population-based study with  $n$  subjects, and  $\{(Y_i, G_i, Z_i) : i = 1, \dots, n\}$  are independent samples. For subjects  $i$  and  $j$ , let  $Y_i$  and  $Y_j$  be their vectors of traits, respectively, and analogously,  $G_i$  and  $G_j$  and  $Z_i$  and  $Z_j$  are their genotypes and covariates. Generalized from Kendall's tau, a  $U$  statistic is defined to measure the association between  $Y$  and  $G$  as follows:

$$U = \binom{n}{2}^{-1} \sum_{i < j} (Y_i - Y_j)(G_i - G_j). \quad (2)$$

Without considering the covariates and conditioning on all phenotypes,  $U$  follows an asymptotically normal distribution

in the absence of association [63]. To accommodate covariates, a weighted  $U$  statistic has been developed [64, 65]. We refer to Jiang and Zhang [64] for a detailed description of the method. For the purpose of comparison, we present the results with and without considering age as the covariate. Recall that our analysis is stratified by ethnicity and gender.

## 4. Results

**4.1. Association Analysis at SNP Level.** Table 2 summarizes the top four significant SNPs (with  $P < 1.0 \times 10^{-4}$ ) in gene *NCK2* on chromosome 2 (2q12) for opiates dependence in African-origin men. We identified a genome-wide significant SNP (rs2377339 with  $P = 1.33 \times 10^{-11}$ ) for the opiates dependence in African-origin men by the allelic test. Logistic regression also yielded strong evidence for the association between the SNP rs2377339 ( $P = 1.01 \times 10^{-7}$ ) and opiates dependence although the  $P$ -value did not reach the genome-wide significance threshold. In addition, Table 2 presents the association results for the other five addictions with the four candidate SNPs. None of the four SNPs appeared significantly associated with the other five substance addictions.

**4.2. Association Analysis at Gene Level.** The gene-based association results are displayed in the last two rows of Table 2. Specifically, we included 39 SNPs in *NCK2*. The  $P$  values from the gene-*NCK2*-based tests that were obtained through the standard allelic test and logistic regression are  $3.12 \times 10^{-10}$  and  $2.70 \times 10^{-6}$ , respectively. The gene-based  $P$  value from the standard allelic test reached the genome-wide significance at gene level. The gene-based  $P$  value through logistic regression is very close to the gene-based genome-wide significance level. Therefore, both methods provided significant evidence that supports the association between the *NCK2* gene and opiates dependence in African-origin men. For the addiction of the other five substances in African-origin men, nicotine dependence had the most significant association with the *NCK2* gene ( $P = 9.56 \times 10^{-3}$ ).

**4.3. Haplotypes Analysis.** We also examined association of haplotypes with opiate addiction in *NCK2* region. Figure 2 displays the linkage disequilibrium (LD) heat map of 14 SNPs

TABLE 2: Association of the most significant SNPs in the NCK2 gene with the six substances dependence in African-origin sen.

Gene	SNP	Method	Alcohol	Cocaine	Marijuana	Nicotine	Opiates	Others	
NCK2	rs2377339	Logistic regression	2.46E - 2	5.09E - 2	4.48E - 2	7.01E - 2	<b>1.10E - 7</b>	3.84E - 3	
		Standard allelic test	6.03E - 3	4.34E - 2	3.89E - 2	6.25E - 2	<b>1.33E - 11</b>	1.78E - 3	
	rs7589342	Logistic regression	2.84E - 1	8.79E - 1	9.35E - 1	8.60E - 1	1.45E - 4	4.26E - 1	
		Standard allelic test	2.81E - 1	8.78E - 1	9.34E - 1	8.59E - 1	5.39E - 5	4.22E - 1	
	rs12995333	Logistic regression	1.71E - 1	7.51E - 1	7.16E - 1	9.86E - 1	1.89E - 4	4.69E - 1	
		Standard allelic test	1.68E - 1	7.51E - 1	7.15E - 1	9.86E - 1	7.82E - 5	4.67E - 1	
	rs12053259	Logistic regression	1.39E - 1	9.43E - 1	7.42E - 1	9.01E - 1	2.31E - 4	4.86E - 1	
		Standard allelic test	1.33E - 1	9.42E - 1	7.39E - 1	9E - 1	8.67E - 5	4.80E - 1	
	NCK2	—	KGG-logistic	1.83E - 1	8.15E - 1	5.92E - 1	9.56E - 3	<b>2.70E - 6</b>	9.45E - 2
	NCK2	—	KGG- Standard allelic test	1.41E - 1	8.16E - 1	4.83E - 1	8.71E - 3	<b>3.12E - 10</b>	4.17E - 2




FIGURE 2: Linkage disequilibrium heat map near SNP rs2377339 on chromosome 2.

TABLE 3: Allele counts of rs2377339 in cases (opiates dependence) and controls (nonopiates dependence) in African-origin men.

	Genotype AA	Genotype AG	Genotype GG	Total
Case	35	9	0	44
Control	483	8	0	491

in 28 kb region [66]. Haplotype “AGTTCAGATCTCGT” with probability 0.016 yielded a  $P$  value of  $1.66 \times 10^{-11}$ . The genome-wide significant association between this haplotype and opiate addiction reduces the chance of a false discovery at the peak of a single SNP.

4.4. Contingency Table Analysis. We further examined the relationship between SNP rs2377339 and the opiates dependence in African-origin men. Table 3 depicts the allele frequencies of SNP rs2377339. The proportion of individuals

having minor allele G is 21.43% in the case group and 1.63% in the control group. The odds ratio of SNP rs2377339 is 13.87, indicating that those who have the risk allele (G) for rs2377339 are at a significantly increased risk of being diagnosed with opiates dependence.

4.5. Stratification Analysis. Furthermore, in Table 4, we investigated the racial specificity and sex difference in the association between SNP rs2377339 and opiates dependence. This scrutiny required us to include all racial and gender groups. We observed that the MAF and  $P$  values vary between different races and genders. The association between rs2377339 and opiates dependence becomes less significant in the overall cohort, after we adjusted race and gender in logistic regression.

4.6. Codependence Association Analysis. In Table 5, we also presented the association results for NCK2 and comorbidity

TABLE 4: Association between SNP rs2377339 and opiates dependence by race and sex.

	MAF	<i>P</i> value	OR
African-origin men	1.59%	$1.33E - 11$	13.87
African-origin women	1.14%	$1.64E - 1$	2.82
European-origin men	6.77%	$8.13E - 2$	0.55
European-origin women	6.64%	$6.95E - 1$	1.14
Combined*	5.04%	$4.37E - 1$	1.17

\*Logistic regression is used to adjust for sex and race.

TABLE 5: Association of most significant SNPs in NCK2 with codependence of six individual substances dependence outcomes (*P* value).

Gene	SNP	position	<i>P</i> value for unadjusted	<i>P</i> value for adjusted
NCK2	rs2377339	105823723	<b><math>3.65E - 8</math></b>	<b><math>2.03E - 8</math></b>
	rs6747023	105798288	$5.43E - 3$	$2.58E - 2$
	rs7589342	105799910	$3.13E - 3$	$1.68E - 2$
	rs12995333	105802798	$3.81E - 3$	$1.83E - 2$

of substance dependence. The most significant signal in *NCK2* was observed for SNP rs2377339 in men of African-origin with  $P = 3.65 \times 10^{-8}$  in adjusted association test and  $P = 2.03 \times 10^{-8}$  in unadjusted association test. *P* values of SNPs in *NCK2* for other ethnicity by gender groups were far from the genome-wide significance level and, hence, are omitted here.

## 5. Discussion

We found a genome-wide significant association between SNP rs2377339 and opiates dependence in African-origin men. The *NCK2* gene that contains SNP rs2377339 also achieved the genome-wide significance for opiates dependence at the gene level. For the addiction of the other five substances, nicotine dependence had the most significant association but not significant at the genome-wide level.

*NCK2*, a member of NCK family of adaptor proteins, is reported to be associated with tyrosine-phosphorylated growth factor receptors of their cellular substrate [54]. The association between *NCK2* and nicotine dependence has been suggested in humans [67, 68]. Our finding coupled with those human studies enhances the plausibility of a causality relationship between *NCK2* and drug addiction.

Importantly, about one-fifth of opiates addiction subjects in the African-origin men carried minor allele G of SNP rs2377339, which is more than 10-fold of the frequency in the nonopiates dependence group. This suggested that the minor allele G in SNP rs2377339 potentially elevates the risk for opiates dependence in African-origin men. We acknowledge that our analysis included only 44 African-origin men with opiates dependence. Therefore, it is important and necessary to validate our finding through independent and larger cohort studies. Specifically, there are two possible strategies to validate our finding. The direct approach is to replicate the

association between SNP rs2377339 and opiates dependence in a larger cohort. An indirect approach is to evaluate whether SNP rs2377339 is associated with any substance dependence (opiates, alcohol, marijuana, etc.) as presented in Table 2.

A distinction of our analysis is to consider simultaneously multiple substance addictions rather than a single substance. This approach, which is a realistic depiction of substance dependence, confirmed that a novel susceptibility gene, *NCK2* is significantly associated with substance dependence in African-origin men.

This study has several limitations. First, we stratified by ethnicity and sex, which reduced sample sizes and affected the power of our analysis. Nonetheless, the significant associations revealed in African-origin men are consistent with the notion that men may be socially more prone to environmental influences that promote substance use and thus more vulnerable to addiction [46]. Second, for SNP rs2377339, we observed heterogeneous genetic effects, suggesting interactions between race, sex, and the gene, because the association is much weakened after adjusting for race and gender. Such interactions have been suggested in other addiction research [44, 45, 47]. Again, our result further supports the importance to examine interactions among genes, race, and sex in addiction.

## Conflict of Interests

The authors declare that they have no conflict of interests.

## Authors' Contribution

Zhifa Liu and Xiaobo Guo contributed equally.

## Acknowledgments

This work was supported by Grant R01 DA016750-09 from the National Institute on Drug Abuse. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative (GEI) (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392), and the Family Study of Cocaine Dependence (FSCD; R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH Contract "High Throughput

Genotyping for Studying the Genetic Contributions to Human Disease" (HHSN268200782096C). The datasets used for the analyses described in this paper were obtained from dbGaP at [http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\\_id=phs000092.v1.p1](http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000092.v1.p1) through dbGaP Accession no. phs000092.v1.p.

## References

- [1] K. R. Merikangas, M. Stolar, D. E. Stevens et al., "Familial transmission of substance use disorders," *Archives of General Psychiatry*, vol. 55, no. 11, pp. 973–979, 1998.
- [2] W. R. True, A. C. Heath, J. F. Scherrer et al., "Interrelationship of genetic and environmental influences on conduct disorder and alcohol and marijuana dependence symptoms," *American Journal of Medical Genetics*, vol. 88, no. 4, pp. 391–397, 1999.
- [3] G. E. Uhl and I. Gregory, "Genetic influences in drug abuse," in *Psychopharmacology: The Fourth Generation of Progress*, pp. 1793–1806, 1995.
- [4] The World Health Organization, "Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention," Annual Report World Health Organization, 2004.
- [5] L. J. Paulozzi, D. S. Budnitz, and Y. Xi, "Increasing deaths from opioid analgesics in the United States," *Pharmacoepidemiology and Drug Safety*, vol. 15, no. 9, pp. 618–627, 2006.
- [6] L. J. Bierut, A. Agrawal, K. K. Buchholz et al., "A genome-wide association study of alcohol dependence," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 11, pp. 5082–5087, 2010.
- [7] X. Chen, K. Cho, B. H. Singer, and H. Zhang, "The nuclear transcription factor PKNOX2 is a candidate gene for substance dependence in European-Origin Women," *PLoS ONE*, vol. 6, no. 1, Article ID e16002, 2011.
- [8] J. Clarimon, R. R. Gray, L. N. Williams et al., "Linkage disequilibrium and association analysis of  $\alpha$ -synuclein and alcohol and drug dependence in two American Indian populations," *Alcoholism: Clinical and Experimental Research*, vol. 31, no. 4, pp. 546–554, 2007.
- [9] D. M. Dick, H. J. Edenberg, X. Xuei et al., "Association of GABRG3 with alcohol dependence," *Alcoholism: Clinical and Experimental Research*, vol. 28, no. 1, pp. 4–9, 2004.
- [10] H. J. Edenberg, D. M. Dick, X. Xuei et al., "Variations in GABRA2, encoding the  $\alpha$ 2 subunit of the GABA a receptor, are associated with alcohol dependence and with brain oscillations," *American Journal of Human Genetics*, vol. 74, no. 4, pp. 705–714, 2004.
- [11] H. J. Edenberg and T. Foroud, "The genetics of alcoholism: identifying specific genes through family studies," *Addiction Biology*, vol. 11, no. 3-4, pp. 386–396, 2006.
- [12] H. J. Edenberg, J. Wang, H. Tian et al., "A regulatory variation in OPRK1, the gene encoding the  $\kappa$ -opioid receptor, is associated with alcohol dependence," *Human Molecular Genetics*, vol. 17, no. 12, pp. 1783–1789, 2008.
- [13] T. Foroud, L. F. Wetherill, T. Liang et al., "Association of alcohol craving with  $\alpha$ -synuclein (SNCA)," *Alcoholism: Clinical and Experimental Research*, vol. 31, no. 4, pp. 537–545, 2007.
- [14] J. Gelernter, R. Gueorguieva, H. R. Kranzler et al., "Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study," *Alcoholism: Clinical and Experimental Research*, vol. 31, no. 4, pp. 555–563, 2007.
- [15] T. Reich, "A genomic survey of alcohol dependence and related phenotypes: results from the Collaborative Study on the Genetics of Alcoholism (COGA)," *Alcoholism: Clinical and Experimental Research*, vol. 20, supplement 8s, pp. 133–137, 1996.
- [16] T. Reich, H. J. Edenberg, A. Goate et al. et al., "Genome-wide search for genes affecting the risk for alcohol dependence," *American Journal of Medical Genetics*, vol. 81, no. 3, pp. 207–215, 1998.
- [17] J. Song, D. L. Koller, T. Foroud et al., "Association of GABAA receptors and alcohol dependence and the effects of genetic imprinting," *American Journal of Medical Genetics*, vol. 117, no. 1, pp. 39–45, 2003.
- [18] B. Tabakoff, L. Saba, M. Printz et al. et al., "Genetical genomic determinants of alcohol consumption in rats and humans," *BMC Biology*, vol. 7, article 70, 2009.
- [19] J. C. Wang, A. L. Hinrichs, S. Bertelsen et al., "Functional variants in TAS2R38 and TAS2R16 influence alcohol consumption in high-risk families of African-American origin," *Alcoholism: Clinical and Experimental Research*, vol. 31, no. 2, pp. 209–215, 2007.
- [20] K. S. Wang, X. F. Liu, Q. Y. Zhang, Y. Pan, N. Aragam, and M. Zeng, "A meta-analysis of two genome-wide association studies identifies 3 new loci for alcohol dependence," *Journal of Psychiatric Research*, vol. 45, no. 11, pp. 1419–1425, 2011.
- [21] H. Zhang, H. R. Kranzler, B. Z. Yang, X. Luo, and J. Gelernter, "The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk," *Molecular Psychiatry*, vol. 13, no. 5, pp. 531–543, 2008.
- [22] G. Kalsi, P. H. Kuo, F. Aliev et al., "A systematic gene-based screen of chr4q22–q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts," *Human Molecular Genetics*, vol. 19, no. 12, pp. 2497–2506, 2010.
- [23] G. Kalsi, P. H. Kuo, F. Aliev et al., "A systematic gene-based screen of chr4q22–q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts," *Human Molecular Genetics*, vol. 19, no. 20, pp. 4121–2506, 2010.
- [24] P. H. Kuo, G. Kalsi, C. A. Prescott et al., "Association of ADH and ALDH genes with alcohol dependence in the Irish affected sib pair study of alcohol dependence (IASPSAD) sample," *Alcoholism: Clinical and Experimental Research*, vol. 32, no. 5, pp. 785–795, 2008.
- [25] L. J. Zuo, J. Gelernter, C. K. Zhang et al. et al., "Genome-wide association study of alcohol dependence implicates IAA0040 on chromosome 1q," *Neuropsychopharmacology*, vol. 37, no. 2, pp. 557–566, 2012.
- [26] L. J. Bierut, "Genetic variation that contributes to nicotine dependence," *Pharmacogenomics*, vol. 8, no. 8, pp. 881–883, 2007.
- [27] L. J. Bierut, P. A. F. Madden, N. Breslau et al., "Novel genes identified in a high-density genome wide association study for nicotine dependence," *Human Molecular Genetics*, vol. 16, no. 1, pp. 24–35, 2007.
- [28] N. Caporaso, F. Gu, N. Chatterjee et al., "Genome-wide and candidate gene association study of cigarette smoking behaviors," *PLoS ONE*, vol. 4, no. 2, Article ID e4653, 2009.
- [29] L. S. Chen, E. O. Johnson, N. Breslau et al., "Interplay of genetic risk factors and parent monitoring in risk for nicotine dependence," *Addiction*, vol. 104, no. 10, pp. 1731–1740, 2009.

- [30] N. L. Saccone, S. F. Saccone, A. L. Hinrichs et al., "Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes," *American Journal of Medical Genetics B*, vol. 150, no. 4, pp. 453–466, 2009.
- [31] S. F. Saccone, A. L. Hinrichs, N. L. Saccone et al., "Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs," *Human Molecular Genetics*, vol. 16, no. 1, pp. 36–49, 2007.
- [32] G. R. Uhl, T. Drgon, C. Johnson et al., "Genome-wide association for smoking cessation success: participants in the patch in practice trial of nicotine replacement," *Pharmacogenomics*, vol. 11, no. 3, pp. 357–367, 2010.
- [33] G. R. Uhl, Q. R. Liu, T. Drgon et al., "Molecular genetics of successful smoking cessation: convergent genome-wide association study results," *Archives of General Psychiatry*, vol. 65, no. 6, pp. 683–693, 2008.
- [34] R. B. Weiss, T. B. Baker, D. S. Cannon et al., "A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction," *PLoS Genetics*, vol. 4, no. 7, Article ID e1000125, 2008.
- [35] I. Deb, J. Chakraborty, P. K. Gangopadhyay, S. R. Choudhury, and S. Das, "Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction," *Journal of Neurochemistry*, vol. 112, no. 2, pp. 486–496, 2010.
- [36] S. Kapur, S. Sharad, R. A. Singh, and A. K. Gupta, "A118G polymorphism in mu opioid receptor gene (OPRM1): association with opiate addiction in subjects of Indian origin," *Journal of Integrative Neuroscience*, vol. 6, no. 4, pp. 511–522, 2007.
- [37] M. J. Kreek, G. Bart, C. Lilly, K. S. Laforge, and D. A. Nielsen, "Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments," *Pharmacological Reviews*, vol. 57, no. 1, pp. 1–26, 2005.
- [38] G. Gerra, C. Leonardi, E. Cortese et al., "Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction," *American Journal of Medical Genetics B*, vol. 144, no. 6, pp. 771–775, 2007.
- [39] V. Yuforov, D. Fussell, K. S. LaForge et al., "Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction," *Pharmacogenetics*, vol. 14, no. 12, pp. 793–804, 2004.
- [40] D. Proudnikov, K. S. LaForge, H. Hofflich et al., "Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes," *Pharmacogenetics and Genomics*, vol. 16, no. 1, pp. 25–36, 2006.
- [41] G. Gerra, L. Garofano, G. Santoro et al., "Association between low-activity serotonin transporter genotype and heroin dependence: behavioral and personality correlates," *American Journal of Medical Genetics*, vol. 126, no. 1, pp. 37–42, 2004.
- [42] E. W. Loh, N. L. S. Tang, D. T. S. Lee, S. I. Liu, and A. Stadlin, "Association analysis of GABA receptor subunit genes on 5q33 with heroin dependence in a Chinese male population," *American Journal of Medical Genetics B*, vol. 144, no. 4, pp. 439–443, 2007.
- [43] C. Y. Cheng, C. J. Hong, Y. W. Y. Yu, T. J. Chen, H. C. Wu, and S. J. Tsai, "Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males," *Molecular Brain Research*, vol. 140, no. 1–2, pp. 86–90, 2005.
- [44] Z. Luo, G. F. Alvarado, D. K. Hatsukami, E. O. Johnson, L. J. Bierut, and N. Breslau, "Race differences in nicotine dependence in the Collaborative Genetic study of Nicotine Dependence (COGEND)," *Nicotine and Tobacco Research*, vol. 10, no. 7, pp. 1223–1230, 2008.
- [45] N. Breslau, E. O. Johnson, E. Hiripi, and R. Kessler, "Nicotine dependence in the United States: prevalence, trends, and smoking persistence," *Archives of General Psychiatry*, vol. 58, no. 9, pp. 810–816, 2001.
- [46] D. M. Hartel, E. E. Schoenbaum, Y. Lo, and R. S. Klein, "Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection," *Clinical Infectious Diseases*, vol. 43, no. 4, pp. 525–531, 2006.
- [47] D. L. Karch, L. Barker, and T. W. Strine, "Race/ethnicity, substance abuse, and mental illness among suicide victims in 13 US states: 2004 data from the national violent death reporting system," *Injury Prevention*, vol. 12, no. 2, pp. 22–27, 2006.
- [48] E. E. Eichler, J. Flint, G. Gibson et al., "Missing heritability and strategies for finding the underlying causes of complex disease," *Nature Reviews Genetics*, vol. 11, no. 6, pp. 446–450, 2010.
- [49] T. A. Manolio, F. S. Collins, N. J. Cox et al., "Finding the missing heritability of complex diseases," *Nature*, vol. 461, no. 7265, pp. 747–753, 2009.
- [50] X. Guo, Z. Liu, X. Wang, and H. Zhang, "Genetic association test for multiple traits at gene level," *Genetic Epidemiology*, vol. 37, no. 1, pp. 122–129, 2013.
- [51] M. X. Li, H. S. Gui, J. S. H. Kwan, and P. C. Sham, "GATES: a rapid and powerful gene-based association test using extended Simes procedure," *American Journal of Human Genetics*, vol. 88, no. 3, pp. 283–293, 2011.
- [52] J. Z. Liu, A. F. McRae, D. R. Nyholt et al., "A versatile gene-based test for genome-wide association studies," *American Journal of Human Genetics*, vol. 87, no. 1, pp. 139–145, 2010.
- [53] B. M. Neale and P. C. Sham, "The future of association studies: gene-based analysis and replication," *American Journal of Human Genetics*, vol. 75, no. 3, pp. 353–362, 2004.
- [54] G. M. Rivera, S. Antoku, S. Gelkop et al., "Requirement of Nck adaptors for actin dynamics and cell migration stimulated by platelet-derived growth factor B," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 25, pp. 9536–9541, 2006.
- [55] H. Begleiter, T. Reich, V. Hesselbrock et al., "The collaborative study on the genetics of alcoholism," *Alcohol Health & Research World*, vol. 19, no. 3, pp. 228–236, 1995.
- [56] L. J. Bierut, J. R. Strickland, J. R. Thompson, S. E. Afful, and L. B. Cottler, "Drug use and dependence in cocaine dependent subjects, community-based individuals, and their siblings," *Drug and Alcohol Dependence*, vol. 95, no. 1–2, pp. 14–22, 2008.
- [57] X. Guo, Z. Liu, X. Wang, and H. Zhang, "Large scale association analysis for drug addiction: results from SNP to gene," *The Scientific World Journal*, vol. 2012, Article ID 939584, 6 pages, 2012.
- [58] S. Purcell, B. Neale, K. Todd-Brown et al., "PLINK: a tool set for whole-genome association and population-based linkage analyses," *American Journal of Human Genetics*, vol. 81, no. 3, pp. 559–575, 2007.
- [59] I. Menashe, J. D. Figueroa, M. Garcia-Closas et al. et al., "Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background," *Plos One*, vol. 7, no. 1, Article ID e29396, 2012.

- [60] A. Christoforou, M. Dondrup, M. Mattingsdal et al. et al., "Linkage-disequilibrium-based binning affects the interpretation of GWASs," *American Journal of Human Genetics*, vol. 90, no. 4, pp. 727–733, 2012.
- [61] F. Dudbridge and A. Gusnanto, "Estimation of significance thresholds for genomewide association scans," *Genetic Epidemiology*, vol. 32, no. 3, pp. 227–234, 2008.
- [62] H. Zhang, C. T. Liu, and X. Wang, "An association test for multiple traits based on the generalized Kendall's tau," *Journal of the American Statistical Association*, vol. 105, no. 490, pp. 473–481, 2010.
- [63] D. Rabinowitz and N. Laird, "A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information," *Human Heredity*, vol. 50, no. 4, pp. 211–223, 2000.
- [64] Y. Jiang and H. Zhang, "Propensity score-based nonparametric test revealing genetic variants underlying bipolar disorder," *Genetic Epidemiology*, vol. 35, no. 2, pp. 125–132, 2011.
- [65] H. Zhao, T. R. Rebbeck, and N. Mitra, "A propensity score approach to correction for bias due to population stratification using genetic and non-genetic factors," *Genetic Epidemiology*, vol. 33, no. 8, pp. 679–690, 2009.
- [66] J. C. Barrett, B. Fry, J. Maller, and M. J. Daly, "Haploview: analysis and visualization of LD and haplotype maps," *Bioinformatics*, vol. 21, no. 2, pp. 263–265, 2005.
- [67] M. Akiyama, K. Yatsu, M. Ota et al., "Microsatellite analysis of the GLC1B locus on chromosome 2 points to NCK2 as a new candidate gene for normal tension glaucoma," *British Journal of Ophthalmology*, vol. 92, no. 9, pp. 1293–1296, 2008.
- [68] S. Bonovas, K. Filioussi, A. Tsantes, and V. Peponis, "Epidemiological association between cigarette smoking and primary open-angle glaucoma: a meta-analysis," *Public Health*, vol. 118, no. 4, pp. 256–261, 2004.





**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

